The pill version of semaglutide just made its European Union debut. On 1 September 2026, Novo Nordisk launched the Wegovy tablet in Germany - the first of the 27 EU member states to get it, and the biggest pharmaceutical market in the bloc. If you have been following the oral GLP-1 story, this is the next chapter.
It follows a tidy sequence: EMA positive opinion in May, European Commission approval in July, and now actual pharmacies in Germany selling the daily tablet. The pill was already on the market in the United States (since January), the United Kingdom and the United Arab Emirates. Germany is the first EU country where it is available.
What the Wegovy pill actually is
The Wegovy tablet is oral semaglutide - the same active ingredient as the injectable Wegovy pen, formulated as a once-daily pill. It is a peptide-based formulation that uses an absorption enhancer called SNAC to help semaglutide survive the stomach. It is not the same as Eli Lilly’s orforglipron (Foundayo), which is a small-molecule GLP-1 agonist rather than a peptide, and which launched in the UK in late August and is under regulatory review in more than 40 markets.
The practical difference matters more than the chemistry. Wegovy tablets need to be taken on an empty stomach with a small amount of water, and you wait about 30 minutes before eating. Orforglipron can be taken with food. For adherence, that 30-minute window is a meaningful friction point, and it is one of the reasons the two products are not interchangeable in the way a casual observer might assume.
Reuters reported that Wegovy pill prices in Germany will vary by dosage and will be comparable to the Wegovy pen, which retails at German pharmacies for roughly EUR 170 to 280 (about AUD 280 to 460). That positioning tells you Novo is not trying to undercut its own injectable - it is trying to capture people who would rather swallow a tablet than inject, and to hold ground against Lilly’s oral challenger.
Why this matters commercially
The oral obesity market is suddenly real. Novo’s own estimate, given when it reported second-quarter earnings in August, is that the Wegovy pill has captured around 90% of the oral obesity market so far. The company also said in January that pills could make up more than a third of total GLP-1 use by 2030.
The US numbers are the proof of concept. Novo launched the pill in the US in January, and by August the company was citing more than five million prescriptions - a pace that led it to hike its 2026 full-year guidance. In its August 5 update, chief executive Mike Doustdar described the Wegovy portfolio as “a key growth driver,” pointing to “continued rapid adoption” of the pill in the US.
None of this guarantees the tablet displaces injectables. The clinical data from the OASIS programme showed oral semaglutide 50mg delivering roughly 15% average weight loss over 68 weeks - solid, but below what injectable tirzepatide has shown at the top end. The tablet is not a stronger drug. It is an easier one, and in the real world, ease of use drives adherence, and adherence drives outcomes.
What the Research Says
The evidence behind the Wegovy pill, in brief:
- Oral semaglutide 50mg produced approximately 15% average body weight loss over 68 weeks in the OASIS 1 trial in adults with obesity or overweight plus at least one comorbidity.
- That sits between injectable semaglutide (typically 15-17% in the STEP programme) and injectable tirzepatide (up to roughly 22.5% at the highest studied doses).
- The EMA and the European Commission cleared the tablet for EU-wide use in 2026, following the UK MHRA and US FDA approvals earlier.
- Novo estimates the pill has captured about 90% of the oral obesity market and projects tablets could exceed one-third of GLP-1 use by 2030.
None of these are therapeutic recommendations. They are the numbers on the table, and the mix of convenience, price and efficacy is exactly what the community should be weighing as more oral options land.
The Australian angle
For Australians, the Germany launch is a reminder that the oral GLP-1 race is happening everywhere except here at scale. The Wegovy tablet is not approved by the TGA, and there is no confirmed timeline for a local launch. The UK pharmacy rollout and now the German launch mean Australians watching from the sidelines are seeing the same pattern repeat: a regulated market somewhere else gets a convenient option, and local demand starts looking for alternatives.
We have covered the Australian access situation and the regulatory gap before, and nothing in the last week changes the fundamentals. What the Germany launch does is widen the gap between what is available in comparable countries and what is available here. If history is any guide, that gap gets filled by compounding pharmacies, telehealth prescribing and the grey market - none of which come with the purity and labelling standards of a regulated launch.
The relevant question for the research community is not whether oral semaglutide “works.” The data says it does, for the people it is approved for, under the conditions it was studied. The relevant question is how people in Australia end up accessing it, and whether what they get matches what was studied. On that front, everyone should be sceptical until the product is tested, labelled and dispensed under something resembling a regulated pathway. Our semaglutide overview covers the compound and its research context if you want the background.
Where the oral race goes next
The next few quarters will be telling. Foundayo is rolling out across markets. Novo is running studies to find the lowest effective dose for its Wegovy pill, and has flagged plans to seek approval in China. AstraZeneca’s elecoglipron is in Phase 3 after a positive Phase 2b. The oral contenders are no longer a sideshow - they are the growth story of the whole category.
As always, none of this is medical advice. It is the state of play, sourced openly, so the community can have an informed conversation. If you want to follow the oral GLP-1 thread with other researchers, the conversation is happening in the Grey Highway Telegram community.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.
Sources: Reuters, “Novo Nordisk launches Wegovy weight-loss pill in Germany”, 1 September 2026 (full text as syndicated by ARY News: https://arynews.tv/wegovy-novo-nordisk-launches-weight-loss-pill-in-germany/). Free Malaysia Today, “Novo Nordisk hikes 2026 forecast on Wegovy pill success”, 5 August 2026: https://www.freemalaysiatoday.com/category/business/2026/08/05/novo-nordisk-hikes-2026-forecast-on-wegovy-pill-success/. Novo Nordisk OASIS 1 trial data as reported by the BMJ, July 2026, and prior Grey Highway coverage of the UK launch.